AR132041A1 - Anticuerpos cd16a y métodos de uso - Google Patents
Anticuerpos cd16a y métodos de usoInfo
- Publication number
- AR132041A1 AR132041A1 ARP240100529A ARP240100529A AR132041A1 AR 132041 A1 AR132041 A1 AR 132041A1 AR P240100529 A ARP240100529 A AR P240100529A AR P240100529 A ARP240100529 A AR P240100529A AR 132041 A1 AR132041 A1 AR 132041A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- binding fragment
- cd16a
- antibody
- construct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno que se unen específicamente a CD16A humana. Reivindicación 1: Un anticuerpo anti-CD16A o fragmento de unión a antígeno del mismo, que comprende un anticuerpo o fragmento de unión del mismo que se une específicamente a CD16A humana. Reivindicación 13: Un constructo que comprende el anticuerpo anti-CD16A o el fragmento de unión a antígeno del mismo de cualquiera de las reivindicaciones precedentes. Reivindicación 18: Una composición farmacéutica que comprende el anticuerpo anti-CD16A o el fragmento de unión a antígeno del mismo de cualquiera de las reivindicaciones precedentes y un portador farmacéuticamente aceptable. Reivindicación 19: Un ácido nucleico aislado que codifica el anticuerpo anti-CD16A o el fragmento de unión a antígeno del mismo o constructo de cualquiera de las reivindicaciones 1 - 17. Reivindicación 20: Un vector que comprende el ácido nucleico de la reivindicación 19. Reivindicación 21: Una célula huésped que comprende el ácido nucleico de la reivindicación 19 o el vector de la reivindicación 20. Reivindicación 22: Un proceso para producir un anticuerpo anti-CD16A o un fragmento de unión a antígeno del mismo que comprende cultivar la célula huésped de la reivindicación 21 y recuperar el anticuerpo o el fragmento de unión a antígeno o el constructo a partir del cultivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023079509 | 2023-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132041A1 true AR132041A1 (es) | 2025-05-21 |
Family
ID=90544635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100529A AR132041A1 (es) | 2023-03-03 | 2024-03-01 | Anticuerpos cd16a y métodos de uso |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20260008853A1 (es) |
| EP (1) | EP4676965A1 (es) |
| CN (1) | CN120813603A (es) |
| AR (1) | AR132041A1 (es) |
| TW (1) | TW202436344A (es) |
| WO (1) | WO2024183636A1 (es) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6602684B1 (en) | 1998-04-20 | 2003-08-05 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
| CA2694488A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| BR112012027001A2 (pt) | 2010-04-23 | 2016-07-19 | Genentech Inc | produção de proteínas heteromultiméricas |
| KR102264570B1 (ko) | 2012-11-28 | 2021-06-14 | 자임워크스 인코포레이티드 | 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도 |
| BR112016027888A2 (pt) | 2014-05-28 | 2017-10-24 | Zymeworks Inc | construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado |
| CN116396393A (zh) | 2015-10-08 | 2023-07-07 | 酵活英属哥伦比亚省公司 | 包含κ和λ轻链的抗原结合多肽构建体及其用途 |
| US20240101677A1 (en) * | 2021-01-27 | 2024-03-28 | Innovent Biologics (Suzhou) Co., Ltd. | Single-domain antibody against cd16a and use thereof |
| WO2023274183A1 (zh) * | 2021-06-29 | 2023-01-05 | 江苏先声药业有限公司 | Cd16抗体及其应用 |
| CN117858902A (zh) * | 2021-08-25 | 2024-04-09 | 南京金斯瑞生物科技有限公司 | 针对人CD16a的抗体及其变体 |
-
2024
- 2024-03-01 WO PCT/CN2024/079594 patent/WO2024183636A1/en not_active Ceased
- 2024-03-01 TW TW113107461A patent/TW202436344A/zh unknown
- 2024-03-01 CN CN202480016076.5A patent/CN120813603A/zh active Pending
- 2024-03-01 AR ARP240100529A patent/AR132041A1/es unknown
- 2024-03-01 EP EP24714767.1A patent/EP4676965A1/en active Pending
-
2025
- 2025-09-02 US US19/315,937 patent/US20260008853A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4676965A1 (en) | 2026-01-14 |
| WO2024183636A1 (en) | 2024-09-12 |
| CN120813603A (zh) | 2025-10-17 |
| US20260008853A1 (en) | 2026-01-08 |
| TW202436344A (zh) | 2024-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| AR111203A1 (es) | Inmunoconjugados | |
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| RU2013111533A (ru) | Способы получения мультиспецифичных и мультивалентных антител | |
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| CR20200324A (es) | Anticuerpos monoclonales y método para utilizar los mismos | |
| MX2022011951A (es) | Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos. | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| AU2019433019A8 (en) | Antibodies binding CD40 and uses thereof | |
| IL273578B1 (en) | Antibodies targeting pdl1 and methods of use thereof | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| MX2022014243A (es) | Proteina de union al antigeno st2. | |
| ZA202308896B (en) | Antibodies binding trop2 and uses thereof | |
| PE20240589A1 (es) | ANTICUERPOS CD1a Y SU USO | |
| BR112023020371A2 (pt) | Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer | |
| BR112021017860A2 (pt) | Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica | |
| AR132064A1 (es) | Anticuerpos anti-cldn6 y métodos de uso | |
| AR132041A1 (es) | Anticuerpos cd16a y métodos de uso | |
| AR125074A1 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR132063A1 (es) | Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso | |
| AR130641A1 (es) | Anticuerpos anti-cd28 |